|
|
||||||||
Department of Internal Medicine I, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
(Correspondence should be addressed to J Klein; Email: j.klein{at}uni-luebeck.de)
* O Senyaman and A Schwartz contributed equally to this work
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The melanocortin (MC) system plays an important role in the regulation of body weight (Butler 2006, Farooqi & O'Rahilly 2006). Moreover, MCs are also pivotal components of the hypothalamo-pituitary–adrenal (HPA) stress axis, and dysregulation of this axis is associated with human obesity (Pasquali et al. 1993, Vicennati & Pasquali 2000, Rosmond 2003).
The MC system consists of the agonistic peptides
, β and
melanocyte-stimulating hormone (MSH) as well as the adrenocorticotrophic hormone (ACTH) which are cleavage products of pro-opiomelanocortin. MCs bind to and activate five MC receptor subtypes (MC1 through 5R). These seven transmembrane G-protein-coupled receptors are distributed in a species- and tissue-specific manner. Furthermore, the system also includes endogenous MC receptor antagonists, agouti and agouti-related protein (Gantz & Fong 2003).
Few reports on direct interactions of MCs with adipocytes have been published. Stimulation of 3T3-L1 cells with MCs has been reported to cause an increase in cAMP concentrations (Boston & Cone 1996, Norman et al. 2003). ACTH and
MSH inhibit leptin expression and secretion in 3T3-L1 cells and primary rat adipocytes (Norman et al. 2003, Hoggard et al. 2004), and induce lipolysis (Boston 1999).
Given a potential direct implication of MCs in the induction of adipose dysfunction, we examined direct actions of ACTH on key metabolic and endocrine adipose responses in white and brown adipocytes respectively. This study demonstrates a direct ACTH-mediated induction of transient insulin resistance, a pro-inflammatory adipokine profile and a p38 mitogen-activated protein kinase (MAPK)-mediated induction of energy combustion.
| Materials and Methods |
|---|
|
|
|---|
All materials were obtained from Sigma–Aldrich unless stated differently.
Cell culture
Immortalised murine adipocyte cell lines were cultured and differentiated as previously described (Klein et al. 1999, 2000, 2002, Jost et al. 2002, Kraus et al. 2002, Perwitz et al. 2006). In brief, the cells were grown to confluence on 10-cm culture plates (Sarstedt, Nümbrecht, Germany) in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 20% foetal bovine serum, 4.5 g/l glucose, 20 nmol/l insulin and 1 nM tri-iodothyronine (differentiation medium). Adipocyte differentiation was induced by complementing the medium further with 250 µmol/l indomethacin, 500 µmol/l isobutylmethylxanthine and 2 µg/ml dexamethasone for 24 h when confluence was reached. After this period, the cells were changed back to differentiation medium. Cell culture was continued for 5 more days, before cells were serum deprived for 24 h prior to carrying out the experiments. Differentiated adipocytes were used between passages 15 and 30. The final concentration of ACTH (Bachem, Bubendorf, Switzerland) was 100 nM. The p38 MAPK inhibitor SB 202190 (Calbiochem, San Diego, CA, USA) was added 1 h prior to ACTH treatment of cells at a final concentration of 10 µM in the respective experiments.
Immunoblotting
Cells were lysed using whole cell lysis buffer containing 2 mM vanadate, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 2 mM phenylmethylsulphonyl fluoride. Protein content of the lysates was determined using the Bradford assay according to the manufacturer's instructions (Bio-Rad). Lysates were subjected to SDS-PAGE and transferred to nitrocellulose membranes (Schleicher and Schuell, Keane, NH, USA). The membranes were incubated overnight with rinsing buffer (10 mM Tris, 150 mM NaCl, 0.05% Tween, pH 7.2) containing 3% BSA (blocking solution). Antibodies were added for 1–2 h in the appropriate dilutions. Protein bands were visualised using a chemiluminescence kit (Roche Molecular Biochemicals). UCP-1 antibody, β-actin antibody and specific MC receptor antibodies were purchased from Chemicon (Temecula, CA, USA). Phospho-specific and total p38 MAPK antibodies were obtained from Cell Signaling (Beverly, MA, USA). Specific aP2 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Densitometry was performed using the programme Quantity One version 4.2.3 (Bio-Rad).
Quantitative real-time reverse transcription PCR
Quantitative real-time RT-PCR was performed, with 36B4 as a housekeeping gene. Total RNA isolation was carried out using TRIzol reagent (Invitrogen). To optimise RNA quality, clean-up and DNase digestion were performed using the RNeasy kit and RNase-Free DNase Set (Qiagen). Quality of RNA was tested by photometric analysis and agarose gel electrophoresis. Two microgram of total RNA were reverse transcribed using Superscript II (Invitrogen) and oligo p(dT)15 primers (Roche Molecular Biochemicals) in the presence of RNase inhibitor (Roche Molecular Biochemicals) in a 20 µl reaction. One microlitre of each RT reaction was amplified in a total volume of 25 µl containing 1x QuantiTect SYBR Green PCR-Mix (Qiagen) and 250 nmol/l of each primer, using the GeneAmp 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The primer sequences are available on request. 36B4 served as housekeeping gene. Identity of the amplified product was confirmed by melting curve analysis and agarose gel electrophoresis. Optimised relative quantification was done using the Relative Expression Software (Pfaffl et al. 2002).
PCR
Qualitative PCRs for MC receptors 1 through 5 were carried out in a Cyclon gradient cycler (Peqlab Biotechnologie GmbH, Erlangen, Germany). Three microlitre of the RT reaction were amplified in a total volume of 30 µl containing 10x Reaction Buffer S (Peqlab Biotechnologie GmbH), 5 U of Taq DNA Polymerase (Peqlab Biotechnologie GmbH), 166 nmol/l of each primer (Biometra, Göttingen, Germany) and 300 µmol/l of each dNTP (Fermentas, St Leon-Rot, Germany). The primer sequences are available on request. The PCR for all targets was performed as follows: initial denaturation at 95 °C for 300 s, 33 cycles with 95 °C for 60 s, 55 °C for 45 s, 72 °C for 60 s and a final elongation step at 72 °C for 420 s.
Determination of interleukin-6 (IL-6) concentrations
IL-6 concentrations were determined using the RayBio Mouse IL-6 ELISA Kit (RayBiotech, Norcross, GA, USA) according to the manufacturer's manual.
Oil red O staining
Tissue culture plates were washed with PBS twice and fixed with 10% formalin for at least 15 min at room temperature. Cells were then stained for 1 h at room temperature with a filtered oil red O solution (stock solution: 0.5 g oil red O in 100 ml isopropyl alcohol, working solution: 60% (v/v) stock solution and 40% (v/v) H2O). The staining solution was washed off the cells with distilled water twice. For densitometry, oil red O stain was eluted with isopropanol and subjected to photometric analysis at 500 nm.
Genomic DNA isolation
Genomic DNA was isolated from pre-adipocytes using the NucleoSpin Tissue kit (Macherey-Nagel, Düren, Germany) according to the manufacturer's instructions.
Glucose uptake
The cells were assayed for glucose uptake essentially as described previously (Klein et al. 1999, Fasshauer et al. 2000). After a serum-free starvation period of 24 h, fully differentiated monolayers of adipocytes were treated with ACTH (100 nM) for various periods of time and then with insulin (100 nM) for 30 min. At the end of the stimulation period, cells were exposed to 2-deoxy-[3H]-D-glucose (0.5 µCi/ml final concentration) for 4 min, and the incorporated radioactivity was determined by liquid scintillation counting.
Statistical analysis
Data are presented as mean±S.D. Sigma Stat-software (SPSS Science, Chicago, IL, USA) was employed for statistical analysis of all data. Statistical significance was determined using the unpaired student's t-test. The values of P<0.05 were considered significant, those <0.01 highly significant.
| Results |
|---|
|
|
|---|
MC 2 and 5 receptors were expressed in both the white and brown adipocytes. By contrast, MC 1, 3 and 4 receptors were not detected at the mRNA level (Fig. 1A).
|
ACTH does not alter differentiation of adipocytes
The up-regulation of MC receptors during adipocyte differentiation prompted us to investigate a possible effect of ACTH on adipogenesis and lipid accumulation. Chronic stimulation of white pre-adipocytes with ACTH during a differentiation period of 6 days did not affect lipid accumulation, as determined microscopically and by oil red O staining with subsequent densitometric evaluation (Fig. 2A). Differentiation markers were also evaluated; PPAR
mRNA and aP2 protein concentrations did not differ significantly between chronically ACTH-treated and control cells (Fig. 2B).
|
Insulin sensitivity is a hallmark of mature adipocytes. Experiments with mature white adipocytes demonstrated a transient reduction in insulin-induced glucose uptake by 45% after ACTH treatment for 1 h (P<0.01). This negative effect subsided after another 3 h (Fig. 3). ACTH treatment for 1 h alone increased glucose uptake by 60% (P<0.05), when compared with untreated cells (Fig. 3).
|
Adipose insulin resistance is closely associated with endocrine dysfunction. We next examined direct effects of ACTH on pro-inflammatory and glucose-regulatory hormones in mature white adipocytes.
Visfatin gene expression was reduced by 50% after 4 h of ACTH stimulation (P<0.01). This effect lasted for another 4 h (Fig. 4A). Adiponectin mRNA concentrations displayed a similar pattern, ACTH significantly decreased adiponectin mRNA levels by 22% after treatment for 2 h (P<0.05). This suppression reached a maximum at 8 h with a reduction of 40% (P<0.001; Fig. 4B).
|
ACTH stimulation increases UCP-1 mRNA in brown adipocytes
The thermogenic brown adipose tissue contributes to energy balance in small mammals and may be associated with insulin sensitivity in human adults (Yang et al. 2003).
Exposure of brown adipocytes to ACTH significantly increased UCP-1 protein concentrations by 170% after 8 h (P<0.01) and maximally by 470% after 24 h (P<0.05; Fig. 5B). This effect was preceded by a transient, maximally 690% rise in UCP-1 mRNA levels between 1 and 8 h of ACTH treatment (P<0.01; Fig. 5A).
|
p38 MAPK pathways have been reported to mediate UCP-1 gene regulation. Using a phospho-specific antibody, an increase in p38 MAPK phosphorylation by 1800% was detectable after 10 min of ACTH treatment (P<0.05; Fig. 6A). Total p38 MAPK content of the cells remained unchanged during this period (Fig. 6A, insert). The ACTH treatment of brown adipocytes for 24 h caused an increase in UCP-1 protein concentrations again, which was abolished by SB 202190, a selective inhibitor of p38 MAPK (P<0.01; Fig. 6B).
|
| Discussion |
|---|
|
|
|---|
To our knowledge, this study is the first to profile MC receptor expression at the protein level. We find MC 2 and 5 receptors, but not 1, 3 and 4 receptors. Our findings are in accordance with previous reports on MC receptor mRNA expression in murine adipose cells (Boston & Cone 1996, Norman et al. 2003). The observed up-regulation of the receptors during differentiation raised the question of an involvement of ACTH in this process. An inhibition of differentiation and adipogenesis of murine pre-adipocytes in the presence of
MSH has previously been reported (Smith et al. 2003). In our study, ACTH did not significantly alter adipogenesis of white adipocytes. This may be due to differences in receptor affinities of
MSH and ACTH: ACTH binds to both receptors, whereas
MSH only binds to MC5R.
Insulin resistance is a key component of the metabolic syndrome and its complications. ACTH caused transient insulin resistance as demonstrated by a decrease in insulin-induced glucose uptake. In vivo, this short-term effect may facilitate an increased availability of glucose to other tissues such as the brain and muscle in physiologically stressful states. An increase in total body energy demand might further be met by previously reported increases in lipolysis mediated by MCs in rodents, in vivo as well as in vitro (White & Engel 1958, Cho et al. 2005).
ACTH stimulation appears to induce a pro-inflammatory adipocyte response. Adiponectin and visfatin have been reported to ameliorate insulin resistance in vivo, and their expression is reduced in subjects with insulin resistance (Fasshauer & Paschke 2003, Hug & Lodish 2005, Klein et al. 2006). Our study provides evidence for an acute decrease in the expression of both adipokines, which could contribute to an overall insulin-resistant state.
By contrast, the pro-inflammatory adipokines IL-6 and MCP-1 are acutely increased by ACTH at the mRNA level. The elevation of IL-6 gene expression is paralleled by an increased IL-6 protein secretion. Effects of IL-6 are complex and appear to be time and tissue specific. Of note, IL-6 production in muscle fibres is increased by exercise, and IL-6 might act as a myocyte-derived exercise factor that increases energy supply for the muscle by enhancing myocyte glucose uptake and β-oxidation of fatty acids (Al-Khalili et al. 2006, Weigert et al. 2006). The IL-6 secretion of adipocytes in states of acute stress might contribute to these effects. On the other hand, chronically increased IL-6 concentrations correlate with an overall insulin-resistant state (Fernandez-Real & Ricart 2003). Elevated MCP-1 levels are also associated with insulin resistance and an inflammatory state (Sartipy & Loskutoff 2003, Kamei et al. 2006, Kanda et al. 2006, Sell et al. 2006, Shoelson et al. 2006). Taken together, ACTH induces an adipokine profile that is associated with insulin resistance and inflammation.
Thermogenesis is mediated by UCP-1 in brown adipocytes and contributes to energy expenditure. Centrally administered MCs are known to increase energy expenditure and UCP-1 gene expression in brown adipocytes of rodents (Pierroz et al. 2002, Williams et al. 2003, Li et al. 2004). This effect is thought to be indirectly mediated via the sympathetic nervous system (Voss-Andreae et al. 2007). We report evidence for a direct induction of UCP-1 gene expression by MCs. This provides a complementary direct mechanism of ACTH action. This finding is further supported by a previous report; peripheral administration of a MC receptor agonist to food-restricted rats prevented the typically observed decrease in UCP-1 (Cettour-Rose & Rohner-Jeanrenaud 2002).
The direct effect of ACTH on the up-regulation of UCP-1 gene activity is mediated by p38 MAPK. ACTH not only increased p38 MAPK phosphorylation by 1800%, but specific inhibition of p38 MAPK also abolished the ACTH-mediated elevation of UCP-1 protein concentration. These findings are in accordance with previous reports on UCP-1 activation (Valladares et al. 2001, Teruel et al. 2003, Cao et al. 2004). Furthermore, PI 3-K and p44/p42 MAPK do not seem to play a role in the ACTH-mediated UCP-1 gene up-regulation, since pharmacological inhibition of these kinases did not affect the ACTH-induced rise of UCP-1 mRNA concentrations.
Taken together, our data provide evidence for direct multi-level effects of ACTH on adipose insulin sensitivity, endocrine function and thermogenesis. This direct crosstalk promotes an insulin-resistant, pro-inflammatory state and transiently enhances energy combustion. In a wider context, these findings provide evidence for direct effects of neuroendocrine peptides on key adipose functions. Direct adipotropic actions of neuropeptides thereby contribute to adipose dysregulation and associated metabolic and cardiovascular disease.
| Acknowledgements |
|---|
| References |
|---|
|
|
|---|
Boston BA 1999 The role of melanocortins in adipocyte function. Annals of the New York Academy of Sciences 885 75–84.[Web of Science][Medline]
Boston BA & Cone R 1996 Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. Endocrinology 137 2043–2050.[Abstract]
Butler AA 2006 The melanocortin system and energy balance. Peptides 27 281–290.[CrossRef][Web of Science][Medline]
Cao W, Daniel KW, Robidoux J, Puigserver P, Medvedev AV, Bai X, Floering LM, Spiegelman BM & Collins S 2004 p38 Mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Molecular and Cellular Biology 24 3057–3067.
Cettour-Rose P & Rohner-Jeanrenaud F 2002 The leptin-like effects of 3-d peripheral administration of a melanocortin agonist are more marked in genetically obese Zucker (fa/fa) than in lean rats. Endocrinology 143 2277–2283.
Cho K-J, Shim J-H, Cho M-C, Choe Y-K, Hong J-T, Moon D-C, Kim J-W & Yoon D-Y 2005 Signaling pathways implicated in alpha-melanocyte stimulating hormone-induced lipolysis in 3T3-L1 adipocytes. Journal of Cellular Biochemistry 96 869–878.[CrossRef][Web of Science][Medline]
Despres J-P & Lemieux I 2006 Abdominal obesity and metabolic syndrome. Nature 444 881–887.[CrossRef][Medline]
Farooqi IS & O'Rahilly S 2006 Genetics of obesity in humans. Endocrine Reviews 27 710–718.
Fasshauer M & Paschke R 2003 Regulation of adipocytokines and insulin resistance. Diabetologia 46 1594–1603.[CrossRef][Web of Science][Medline]
Fasshauer M, Klein J, Ueki K, Kriauciunas KM, Benito M, White MF & Kahn CR 2000 Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. Journal of Biological Chemistry 275 25494–25501.
Fernandez-Real JM & Ricart W 2003 Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews 24 278–301.
Gantz I & Fong TM 2003 The melanocortin system. American Journal of Physiology. Endocrinology and Metabolism 284 E468–E474.
Hoggard N, Hunter L, Duncan J & Rayner D 2004 Regulation of adipose tissue leptin secretion by alpha-melanocyte-stimulating hormone and agouti-related protein: further evidence of an interaction between leptin and the melanocortin signalling system. Journal of Molecular Endocrinology 32 145–153.[Abstract]
Hug C & Lodish HF 2005 The role of the adipocyte hormone adiponectin in cardiovascular disease. Current Opinion in Pharmacology 5 129–134.[CrossRef][Web of Science][Medline]
Jost P, Fasshauer M, Kahn CR, Benito M, Meyer M, Ott V, Lowell BB, Klein HH & Klein J 2002 A typical beta-adrenergic effects on insulin signaling and action in beta 3-adrenoceptor-deficient brown adipocytes. American Journal of Physiology. Endocrinology and Metabolism 283 E146–E153.
Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M et al. 2006 Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. Journal of Biological Chemistry 281 26602–26614.
Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K-I, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K et al. 2006 MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. Journal of Clinical Investigation 116 1494–1505.[CrossRef][Web of Science][Medline]
Klein J, Fasshauer M, Ito M, Lowell BB, Benito M & Kahn CR 1999 β3-Adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. Journal of Biological Chemistry 274 34795–34802.
Klein J, Fasshauer M, Benito M & Kahn CR 2000 Insulin and the beta3-adrenoceptor differentially regulate uncoupling protein-1 expression. Molecular Endocrinology 14 764–773.
Klein J, Fasshauer M, Klein HH, Benito M & Kahn CR 2002 Novel adipocyte lines from brown fat: a model system for the study of differentiation, energy metabolism, and insulin action. BioEssays 24 382–388.[CrossRef][Web of Science][Medline]
Klein J, Perwitz N, Kraus D & Fasshauer M 2006 Adipose tissue as source and target for novel therapies. Trends in Endocrinology and Metabolism 17 26–32.[CrossRef][Web of Science][Medline]
Kraus D, Fasshauer M, Ott V, Meier B, Jost M, Klein H & Klein J 2002 Leptin secretion and negative autocrine crosstalk with insulin in brown adipocytes. Journal of Endocrinology 175 185–191.[Abstract]
Li G, Zhang Y, Wilsey J & Scarpace P 2004 Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression. Journal of Endocrinology 182 123–132.[Abstract]
Norman D, Isidori AM, Frajese V, Caprio M, Chew SL, Grossman AB, Clark AJ, Besser MG & Fabbri A 2003 ACTH and (alpha)-MSH inhibit leptin expression and secretion in 3T3-L1 adipocytes: model for a central–peripheral melanocortin-leptin pathway. Molecular and Cellular Endocrinology 200 99–109.[CrossRef][Web of Science][Medline]
Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, Labate A & Barbara L 1993 The hypothalamic–pituitary–adrenal axis in obese women with different patterns of body fat distribution. Journal of Clinical Endocrinology and Metabolism 77 341–346.[Abstract]
Perwitz N, Fasshauer M & Klein J 2006 Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Hormone and Metabolic Research 38 356–358.[CrossRef][Web of Science][Medline]
Pfaffl MW, Horgan GW & Dempfle L 2002 Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Research 30 e36.
Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS & Mantzoros CS 2002 Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 51 1337–1345.
Rosmond R 2003 Stress induced disturbances of the HPA axis: a pathway to type 2 diabetes? Medical Science Monitor 9 RA35–RA39.
Sartipy P & Loskutoff DJ 2003 Monocyte chemoattractant protein 1 in obesity and insulin resistance. PNAS 100 7265–7270.
Sell H, Dietze-Schroeder D, Kaiser U & Eckel J 2006 Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 147 2458–2467.
Shoelson SE, Lee J & Goldfine AB 2006 Inflammation and insulin resistance. Journal of Clinical Investigation 116 1793–1801.[CrossRef][Web of Science][Medline]
Smith SR, Gawronska-Kozak B, Janderova L, Nguyen T, Murrell A, Stephens JM & Mynatt RL 2003 Agouti expression in human adipose tissue: functional consequences and increased expression in type 2 diabetes. Diabetes 52 2914–2922.
Teruel T, Hernandez R, Benito M & Lorenzo M 2003 Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes. Journal of Biological Chemistry 278 263–269.
Valladares A, Roncero C, Benito M & Porras A 2001 TNF-(alpha) inhibits UCP-1 expression in brown adipocytes via ERKs: opposite effect of p38MAPK. FEBS Letters 493 6–11.[CrossRef][Web of Science][Medline]
Vicennati V & Pasquali R 2000 Abnormalities of the hypothalamic–pituitary–adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. Journal of Clinical Endocrinology and Metabolism 85 4093–4098.
Voss-Andreae A, Murphy JG, Ellacott KLJ, Stuart RC, Nillni EA, Cone RD & Fan W 2007 Role of the central melanocortin circuitry in adaptive thermogenesis of brown adipose tissue. Endocrinology 148 1550–1560.
Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, Haring HU & Schleicher ED 2006 Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. Journal of Biological Chemistry 281 7060–7067.
White JE & Engel FL 1958 Lipolytic action of corticotropin on rat adipose tissue in vitro. Journal of Clinical Investigation 37 1549–1555.[Web of Science][Medline]
Williams DL, Bowers RR, Bartness TJ, Kaplan JM & Grill HJ 2003 Brainstem melanocortin 3/4 receptor stimulation increases uncoupling protein gene expression in brown fat. Endocrinology 144 4692–4697.
Yang X, Enerback S & Smith U 2003 Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance. Obesity Research 11 1182–1191.[Web of Science][Medline]
Received in final form 14 November 2007
Accepted 19 December 2007
Made available online as an Accepted Preprint 19 December 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |